(Stat News) “How does one balance some of the logistical and possible efficacy benefits of donanemab against the doubling of ARIA? I don’t have an answer,” he told STAT’s Adam Feuerstein. Is the cure worse than the disease?
(Stat News) “How does one balance some of the logistical and possible efficacy benefits of donanemab against the doubling of ARIA? I don’t have an answer,” he told STAT’s Adam Feuerstein. Is the cure worse than the disease?